![]()
|
Report Date : |
02.09.2011 |
IDENTIFICATION DETAILS
|
Name : |
SHROOQ
PHARMACEUTICALS (PVT.) LIMITED |
|
|
|
|
Registered Office : |
21
K.M., Ferozepur Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
2003 |
|
|
|
|
Com. Reg. No.: |
0045795 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture
& Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SHROOQ PHARMACEUTICALS (PVT.) LIMITED
Registered Address
|
|
21
K.M., Ferozepur Road, Lahore, Pakistan |
|
Tel # |
92 (42) 35274026 - 29 (4
Lines) |
|
Fax # |
92
(42) 35274031 |
|
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
Year Established |
2003 |
|
Registration No. |
0045795 |
|
In Lahore at present |
|
Imran Saeed & Co. (Chartered Accountants) 2nd Floor, Mian Chambers, Block-19, 3-Temple Road, Lahore,
Pakistan |
|
Subject Company was established as a Private Limited Company in 2003 |
|
Authorized Capital |
Rs. 5,000,000/- divided
into 50,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 5,000,000/-
divided into 50,000 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Riaz Ahmad Mrs. Anjum Riaz |
Pakistani Pakistani |
21 K.M., Ferozpur Road,
Lahore, Pakistan 21 K.M., Ferozpur Road, Lahore, Pakistan |
Business Business |
Chief Executive Director |
|
Names |
No. of Shares |
|
Mr. Riaz Ahmad Mrs. Anjum Riaz |
30,000 20,000 |
A. Subsidiary
None
B. Associated
Companies
- Do
-
Manufacture & Marketing of Pharmaceutical
Products by its brand names of AEROMAX,
ALBICOST, ALBIMIN, ARVID, BDCEF, BRUNAC, CEFMOR, CHASE, CLINZE, DANVAR,
DERMOVAL, DISPERSEN, DOME-ONE, DOMINO, FUZAC, FUZAC-B, GETRAN, ISOCEF, ISOGEN,
LAVILOX, LORTIN-D, LORTIN-P, LOXIDOL, METICAL, MOVAREN, MOVEN, NEOPENTINE,
NOVARISE, OCCUNET, ORINA, PENTIUN, PULMAX, RAYOVIT, REMAST, REMAST-P, RISEN,
SANSI, SMYLE, TIFOX, ZANDOL
79
The capacity and production of the company’s
plant is indeterminable as it involves varying processes of manufacture.
|
Year |
In Pak Rupees |
|
2009 |
120,000,000/- (Estimated) |
|
Mainly exist at major cities of Pakistan |
(1) Habib Metropolitan Bank Limited, Pakistan.
(2) Habib Bank Limited, Pakistan.
(3) MCB Bank Limited, Pakistan.
(4) Standard Chartered Bank, Pakistan.
(5)
Bank
Alfalah Limited, Pakistan.
·
Lahore Chamber of Commerce & Industry.(
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 86.65 |
|
UK Pound |
1 |
Rs. 141.80 |
|
Euro |
1 |
Rs. 125.20 |
Subject Company was
established in 2003 and is engaged in manufacture & marketing of
Pharmaceutical Products. Market reputation is satisfactory. Trade relations are
reported as fair. Subject can be considered for normal business dealings at
usual trade terms & conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.46.01 |
|
|
1 |
Rs.75.42 |
|
Euro |
1 |
Rs.66.69 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.